The Cancer Immunology Program is one of the longstanding components of the NYUCI, with 38 members from 9 Departments. This program has recently been expanded by the vigorous recruitment in Immunology conducted by the NYUCI and also the Department of Pathology, to new or newly renovated space. 12 faculty have been added to the Program in the past year;9 of these are new recruits brought to NYU School of Medicine from outstanding institutions such as Harvard, Stanford, Yale, UCSF, and others. Goals of the Cancer Immunology Program are: 1) to understand the biology of, more effectively diagnose, and develop treatments for neoplasms arising from cells of the lymphoid and myeloid system, 2) to understand the biology of tumor rejection, including the mechanisms used by tumors to evade the immune system;3) to effectively manipulate the immune system to promote immunotherapy of tumors. The program is subdivided into three thematic areas reflecting this tripartite mission. Members of this program collaborate extensively with other.NYUCI Programs, especially Growth Control, Breast Cancer, Neurooncology, and Melanoma. The Cancer Immunology Group has been highly productive, generating over 319 publications from 2002-2006 and has increased outside funding from $4.8 M in 2002 to $10.4 M in 2006. Total funding has increased from $7,128,048 to $11,674,122. Membership has increased from 17 to 38. Total publications for the past five years include 319 of which 4% are intra-programmatic and 15% are interprogrammatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-31
Application #
8232193
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-03-01
Budget End
2012-02-29
Support Year
31
Fiscal Year
2011
Total Cost
$23,332
Indirect Cost
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Huang, Chao; Zeng, Xingruo; Jiang, Guosong et al. (2017) XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell. J Hematol Oncol 10:6
Silvera, Deborah; Ernlund, Amanda; Arju, Rezina et al. (2017) mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells. Mol Cell Biol 37:
Koh, Hyunwook; Blaser, Martin J; Li, Huilin (2017) A powerful microbiome-based association test and a microbial taxa discovery framework for comprehensive association mapping. Microbiome 5:45
Ma, Lijie; Liu, Yan; Landry, Nichole K et al. (2017) Point mutation in D8C domain of Tamm-Horsfall protein/uromodulin in transgenic mice causes progressive renal damage and hyperuricemia. PLoS One 12:e0186769
Morabito, Michael V; Ravussin, Yann; Mueller, Bridget R et al. (2017) Weight Perturbation Alters Leptin Signal Transduction in a Region-Specific Manner throughout the Brain. PLoS One 12:e0168226
Koetz-Ploch, Lisa; Hanniford, Douglas; Dolgalev, Igor et al. (2017) MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res 30:328-338
Feig, Jessica L; Mediero, Aranzazu; Corciulo, Carmen et al. (2017) The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin. PLoS One 12:e0188135
Ono, Kentaro; Viet, Chi T; Ye, Yi et al. (2017) Cutaneous pigmentation modulates skin sensitivity via tyrosinase-dependent dopaminergic signalling. Sci Rep 7:9181
Wang, Xing; Zhang, Fenglin; Wu, Xue-Ru (2017) Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin. Sci Rep 7:45983
Garré, Juan Mauricio; Silva, Hernandez Moura; Lafaille, Juan J et al. (2017) CX3CR1+ monocytes modulate learning and learning-dependent dendritic spine remodeling via TNF-?. Nat Med 23:714-722

Showing the most recent 10 out of 1082 publications